CSL Ltd
ASX:CSL
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
170.77
288.33
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
CSL
stock under the Base Case scenario is
223.62
AUD.
Compared to the current market price of 171.48 AUD,
CSL Ltd
is
Undervalued by 23%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for CSL Ltd.
| FR |
|
Pharnext SCA
OTC:PNEXF
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
|
| US |
S
|
Seagen Inc
F:SGT
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
CSL’s heavy dependence on plasma collection for its immunoglobulin and plasma-derived therapeutics creates a persistent risk of supply disruptions and higher costs, particularly in regions where donor compensation policies might shift.
Increasing competition from other plasma-focused companies such as Grifols and Takeda threatens CSL’s pricing power and could erode margins if rivals expand capacity or introduce new treatments more rapidly.
R&D efforts are capital-intensive and carry the potential for high-profile failures, which may slow CSL’s growth if pipeline projects like advanced gene therapies for rare diseases do not meet clinical or regulatory milestones.
CSL’s global leadership in plasma-derived therapeutics and vaccines, supported by its extensive plasma-collection network, provides a durable competitive advantage and a reliable revenue base.
Continued success in new product launches, including next-generation gene therapies and high-demand influenza vaccines, has the potential to solidify CSL’s market position and diversify its earnings streams.
Strategic acquisitions such as Vifor Pharma, combined with ongoing investments in next-generation treatments, could unlock further synergies, bolster CSL’s portfolio in rare diseases, and strengthen its global market reach.
Revenue & Expenses Breakdown
CSL Ltd
Balance Sheet Decomposition
CSL Ltd
| Current Assets | 11.9B |
| Cash & Short-Term Investments | 2.2B |
| Receivables | 3.2B |
| Other Current Assets | 6.5B |
| Non-Current Assets | 27.6B |
| Long-Term Investments | 203m |
| PP&E | 9.8B |
| Intangibles | 16.2B |
| Other Non-Current Assets | 1.4B |
| Current Liabilities | 4.8B |
| Accounts Payable | 3.5B |
| Other Current Liabilities | 1.4B |
| Non-Current Liabilities | 15.3B |
| Long-Term Debt | 10.7B |
| Other Non-Current Liabilities | 4.6B |
Free Cash Flow Analysis
CSL Ltd
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
CSL Ltd
|
Revenue
|
15.6B
USD
|
|
Cost of Revenue
|
-7.5B
USD
|
|
Gross Profit
|
8.1B
USD
|
|
Operating Expenses
|
-4B
USD
|
|
Operating Income
|
4.1B
USD
|
|
Other Expenses
|
-1.1B
USD
|
|
Net Income
|
3B
USD
|
CSL Profitability Score
Profitability Due Diligence
CSL Ltd's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
Score
CSL Ltd's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
CSL Solvency Score
Solvency Due Diligence
CSL Ltd's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Score
CSL Ltd's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CSL Price Targets Summary
CSL Ltd
According to Wall Street analysts, the average 1-year price target for
CSL
is 244.21 AUD
with a low forecast of 189.88 AUD and a high forecast of 308.92 AUD.
Dividends
Current shareholder yield for
CSL is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
CSL
stock under the Base Case scenario is
223.62
AUD.
Compared to the current market price of 171.48 AUD,
CSL Ltd
is
Undervalued by 23%.